Corticosteroids Market Size - By Product (Glucocorticoids, Mineralocorticoids), Route of Administration (Topical, Injectable, Oral, Inhaled), Application (Skin Allergies, Rheumatology Indications), Distribution Channel & Forecast, 2024 – 2032

Corticosteroids Market Size

Corticosteroids Market size was valued at USD 5.2 billion in 2023 and is expected to grow at a CAGR of 7.5% between 2024 and 2032. The rising incidence of chronic diseases and the increasing prevalence of cancers are some of the key factors expected to drive the growth of the market.
 

The prevalence of chronic diseases is rapidly increasing globally, attributed to factors like poor health behaviors, genetic predisposition, environmental influences, and lifestyle choices. Chronic conditions such as heart disease, cancer, and diabetes are leading drivers of the nation’s USD 4.1 trillion in annual healthcare costs. Additionally, cancer, including common types like prostate, breast, melanoma (skin), uterine, colon, rectum, thyroid, bladder, non-Hodgkin lymphoma, kidney, ovarian, and lung cancers, contributes significantly to this trend.
 

According to the Centers for Disease Control and Prevention (CDC), in 2020 alone, there were 1.6 million new cancer cases reported, and 0.6 million people died of cancer in the U.S. This rise in the prevalence of such conditions is fueling the demand for corticosteroids, thereby expected to drive market growth.
 

Corticosteroids are a class of steroid hormones produced naturally in the adrenal cortex of vertebrates or synthesized for medical use. They play a vital role in regulating various physiological processes, including metabolism, immune response, and stress response.
 

Corticosteroids Market Trends

Pharmaceutical companies are actively working towards sustainable practices in drug development and manufacturing, to develop more effective, targeted, and novel drug delivery approaches.
 

• There is a shift towards more eco-friendly drug formulations in the pharmaceutical industry. For instance, two new steroid compounds, called SCA and SCB, were created via biotransformation of cortisone using microorganisms. These compounds exhibit anti-inflammatory, antioxidant, and neuroprotective properties, making them promising alternatives to conventional corticosteroids with fewer side effects.
   
• Additionally, recent advancements focus on improving connected drug delivery systems for corticosteroids, particularly in topical and inhaler formulations. For instance, the mucoadhesive polymer patches for improved delivery of topical corticosteroids. These patches offer prolonged and controlled drug delivery, enhancing local bioavailability and safety profiles. They provide advantages such as targeted drug release, reduced systemic absorption, biodegradability, and dissolution of the polymeric platform during drug release.
   

Corticosteroids Market Analysis

Based on products, the market is segmented into glucocorticoids and mineralocorticoids. The glucocorticoids segment is anticipated to reach USD 8.9 billion by 2032.
 

• There is an increase in the prevalence of conditions like rheumatoid arthritis, inflammatory bowel disease, asthma, and allergic reactions, glucocorticoids. For instance, in 2019, 18 million people worldwide were living with rheumatoid arthritis. These population utilizes glucocorticoids to manage symptoms and alleviate inflammation and immune responses.
   
• Moreover, improved awareness and diagnostic techniques have led to more accurate diagnosis and recognition of conditions that may benefit from glucocorticoid therapy. This increased awareness contributes to higher demand for these medications.
   

Based on route of administration, the corticosteroids market is segmented into topical, injectable, oral, and inhaled. The topical segment dominated around USD 2.4 billion revenue in 2023.
 

• The primary factors increasing the demand for topical segment is the increased patient preference. For instance, their availability in numerous formulations such as creams, ointments, lotions, and gels are easy to apply and provide convenience for patients. hence propel their demand in the market.
   
• Additionally, pharmaceutical companies are expanding their market reach for topical corticosteroids through marketing efforts, distribution networks, and partnerships with healthcare providers. This expansion increases product availability and accessibility, further driving demand.
   

Based on application, the corticosteroids market is segmented into skin allergies, gastroenterology, endocrinology, acute respiratory diseases, rheumatology indications, and other applications. The skin allergies segment is expected to cross USD 3 billion by 2032.
 

• Skin conditions such as eczema, psoriasis, dermatitis, and acne are common worldwide. The increase in the prevalence of these conditions are growing the demand for corticosteroids as it is a primary treatment approach for skin conditions including acne medication, hence set to propel the market.

• Additionally, growing consumer awareness of skin allergies and their impact on quality of life has led to increased demand for effective treatments. People are seeking medical attention for their skin allergies may contributing the segmental growth.

The corticosteroids market by distribution channel is categorized into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment dominates the market with a revenue of around USD 2.5 billion in 2023.
 

• Corticosteroids are potent medications that require careful monitoring, dosage adjustments, and often, specialized administration techniques. Hospital pharmacies are equipped with trained pharmacists who have the expertise to manage these complexities and ensure safe and effective use of corticosteroids, particularly for patients with severe or complex medical conditions.   

• Moreover, in some cases, corticosteroids may need to be compounded into specialized formulations or dosages to meet the specific needs of patients, particularly in pediatric or geriatric populations. Hospital pharmacies have the facilities and expertise to perform compounding as necessary, due to which large number of patients prefer hospital pharmacies anticipating them as a dominant distribution channel in the market.

North America corticosteroids market accounted for USD 1.9 billion revenue in 2023 and is predicted to witness substantial growth over the analysis timeline.
 

• The promising market potential and long-term revenue opportunities associated with corticosteroid therapies have attracted significant investor interest, leading to increased funding for R&D initiatives in North America.
   
• Furthermore, regulatory agencies in region, such as the U.S. Food and Drug Administration (FDA) and Health Canada, are actively supporting R&D initiatives for corticosteroids by providing expedited review pathways, regulatory guidance, and incentives for orphan drug development. This regulatory support is anticipated to drive the market growth in the region.
   

Corticosteroids Market Share

The corticosteroids industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced product based on different technologies is among a key market strategy. Some of the leading industry players including AbbVie Inc., Astellas Pharma Inc., Novartis AG, Pfizer Inc., and Eli Lilly and Company among others have a notable presence in the market.
 

Corticosteroids Market Companies

Some of the eminent market participants operating in the corticosteroids industry include:

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bausch Health Companies Inc.
• Bayer AG
• Cipla Limited
• Eli Lilly and Company
• GlaxoSmithKline plc
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
   

Corticosteroids Industry News

• In July 2023, Lupin launched Luforbec 100/6, a pressurized metered dose inhaler (pMDI) containing beclometasone 100 μg and formoterol 6 μg, for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. This launch marks the first-ever product launch in the inhalation segment for Lupin in Germany and is expected to enhance the company’s market presence in the market.
   
• In January 2023, Lupin introduced DIFIZMA DPI, a novel fixed-dose triple drug combination for the treatment of inadequately controlled asthma. This launch is expected to improve the company’s treatment offerings and enable more customer base.
   

The corticosteroids market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Glucocorticoids
• Mineralocorticoids

Market, By Route of Administration

• Topical
• Injectable
• Oral
• Inhaled

Market, By Application

• Skin allergies
• Gastroenterology
• Endocrinology
• Acute respiratory diseases
• Rheumatology indications
• Other applications

Market, By Distribution channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information has been provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa